Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>We see 38 potential and close adds and 51 potential and close deletes for the Hang Seng Composite Index in March. Some of the stocks are close on market cap/liquidity.</li>
<li>There have been many new listings in the last weeks of December. Some of them are fairly large and will be added and that increases the number of potential deletions.</li>
<li>There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.</li>
</ul>


We see 38 potential and close adds and 51 potential and close deletes for the Hang Seng Composite Index in March. Some of the stocks are close on market cap/liquidity.
There have been many new listings in the last weeks of December. Some of them are fairly large and will be added and that increases the number of potential deletions.
There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.


HSCI Index Rebalance Preview and Stock Connect: Updated Potential Changes in March 2025

<ul>
<li>We see 32 potential and close adds and 44 potential and close deletes for the Hang Seng Composite Index in March. Some of the stocks are close on market cap/liquidity.</li>
<li>We expect 29 stocks to be added to Southbound Stock Connect following the rebalance while 31 stocks could be deleted from the trading link and become Sell-only.</li>
<li>There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.</li>
</ul>


We see 32 potential and close adds and 44 potential and close deletes for the Hang Seng Composite Index in March. Some of the stocks are close on market cap/liquidity.
We expect 29 stocks to be added to Southbound Stock Connect following the rebalance while 31 stocks could be deleted from the trading link and become Sell-only.
There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.


HSCI Index Rebalance Preview and Stock Connect: Potential Changes in March 2025

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Malo Medical Management / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/malo-medical-management" target="_blank" data-smartkarma-citation="entities:40035:1" rel="noopener">Malo Medical Management (MMM HK)</a> (MMM) is looking to raise around US$100m (estimated) in its upcoming Hong Kong IPO. The deal will be run by Haitong.</li>
<li>MMM is a dental service provider in China. It ranked ninth among all private dental service providers and second among all premium dental service providers, as per F&amp;S.</li>
<li>MMM provides dental services to patients through a widespread network of Malo Clinic-branded specialty dental clinics. As of Apr 2023, it owned 29 dental clinics in 13 cities in China.</li>
</ul>



Malo Medical Management (MMM HK) (MMM) is looking to raise around US$100m (estimated) in its upcoming Hong Kong IPO. The deal will be run by Haitong.
MMM is a dental service provider in China. It ranked ninth among all private dental service providers and second among all premium dental service providers, as per F&amp;S.
MMM provides dental services to patients through a widespread network of Malo Clinic-branded specialty dental clinics. As of Apr 2023, it owned 29 dental clinics in 13 cities in China.


Malo Medical Management Pre-IPO Tearsheet

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

SenseTime Group  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sensetime-group" target="_blank" data-smartkarma-citation="entities:34319:1" rel="noopener">SenseTime Group (1475539D HK)</a> has relaunched its HKEx IPO with an unchanged IPO price range and target raise of up to US$768 million. Pricing is set for 23 December.</li>
<li>In <a href="https://www.smartkarma.com/insights/sensetime-ipo-initiation-big-brother" target="_blank" data-smartkarma-citation="insights:62104" rel="noopener">SenseTime IPO Initiation: Big Brother</a>, we stated that the negatives outweigh the positives and we would give the IPO a pass.</li>
<li>Our base-case DCF value is HK$3.48 per share, -11% below the mid-point of the IPO price range. Our DCF sensitivity analysis shows that the IPO price remains unattractive.   </li>
</ul>



SenseTime Group (1475539D HK) has relaunched its HKEx IPO with an unchanged IPO price range and target raise of up to US$768 million. Pricing is set for 23 December.
In SenseTime IPO Initiation: Big Brother, we stated that the negatives outweigh the positives and we would give the IPO a pass.
Our base-case DCF value is HK$3.48 per share, -11% below the mid-point of the IPO price range. Our DCF sensitivity analysis shows that the IPO price remains unattractive.   


SenseTime IPO: Relaunched but Remains a Pass

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Chaoju Eye Care Holdings / Equity Capital Markets

<p>On January 4<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/chaoju-eye-care-holdings-limited" target="_blank" data-smartkarma-citation="entities:31119:1" rel="noopener">Chaoju Eye Care Holdings (CEC HK)</a> filed a prospectus with the Hong Kong Stock Exchange for listing on the Main Board. The Company's history could be traced back to the time when Zhang Xinghuan, the father of Chaoju's  founder, began his practice as a traditional Chinese medicine practitioner and then established a Chinese medicine clinic in 1921. Following in the footsteps of his father, Zhang Chaoju, as a pioneer of modern ophthalmology in Inner Mongolia and an entrepreneur in the field of ophthalmology services in China, founded a clinic that provided ophthalmology services in Baotou City, Inner Mongolia in 1988. Since then, Chaoju Eye Care has established an extensive network of ophthalmic hospitals and optical centers in North China. Regardless of the long history and professional background, how about this Company? The following mainly analyzed both the strengths and concerns for Chaoju.</p>

On January 4th, 2021, Chaoju Eye Care Holdings (CEC HK) filed a prospectus with the Hong Kong Stock Exchange for listing on the Main Board. The Company's history could be traced back to the time when Zhang Xinghuan, the father of Chaoju's  founder, began his practice as a traditional Chinese medicine practitioner and then established a Chinese medicine clinic in 1921. Following in the footsteps of his father, Zhang Chaoju, as a pioneer of modern ophthalmology in Inner Mongolia and an entrepreneur in the field of ophthalmology services in China, founded a clinic that provided ophthalmology services in Baotou City, Inner Mongolia in 1988. Since then, Chaoju Eye Care has established an extensive network of ophthalmic hospitals and optical centers in North China. Regardless of the long history and professional background, how about this Company? The following mainly analyzed both the strengths and concerns for Chaoju.

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

China

C-Mer Eye Care Holdings Limited provides general medical and surgical hospital services. The Hospital offers eye disease examination, treatment, and other medical services. C-Mer Eye Care Holdings serves patients in Hong Kong.

C-Mer Eye Care Holdings Limited  (3309 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

C-Mer Eye Care Holdings Limited (3309 HK)

HSCI Index Rebalance Preview and Stock Connect: Updated Potential Changes in March 2025

There could be 89 changes for the HSCI in March. That could result in 73 changes to the Southbound Stock Connect list and also have implications...

Brian Freitas

HSCI Index Rebalance Preview and Stock Connect: Potential Changes in March 2025

There could be 78 changes for the HSCI in March. That could result in 57 changes to the Southbound Stock Connect list and also have implications...

Brian Freitas

Malo Medical Management Pre-IPO Tearsheet

Malo Medical Management (MMM HK) is looking to raise around US$100m (estimated) in its upcoming Hong Kong IPO. The deal will be run by Haitong.

Sumeet Singh

SenseTime IPO: Relaunched but Remains a Pass

SenseTime has relaunched its HKEx IPO with an unchanged IPO price range and target raise of up to US$768 million. Our DCF sensitivity analysis...

Arun George

Pre-IPO Chaoju Eye Care Holdings - Here Are the Strength and the Concerns

This article analyzed Chaoju Eye Care in terms of both the strength (market position, financial position) and the concerns (risk of future...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)